Back

The Drug-Induced Respiratory Disease Website and App

VII.a

VII - Mediastinal involvement

Lymphadenopathy (intrathoracic)

Last update 17/06/2026

Can be hilar and/or mediastinal. Typically detected on imaging. Pathology may reveal granulomatous or reactive changes

Causative drugs

27

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

BCG therapy (topical instillations in the urinary bladder)
I.a
I.b
I.c
I.l
I.m
II.b
IV.d
V.a
VII.a
VII.e
VIII.c
IX.r
IX.ab
X.g
X.l
X.m
X.u
XV.e
XV.f
XV.ba
XV.cg
XVI.u
XVI.ai
XVII.f
XVII.i
XIX.a
Breast implants - Augmentation mammaplasty (w/wo evidence for leakage/rupture)
I.b
I.c
I.n
I.al
I.am
II.t
III.a
V.a
V.v
V.w
VII.a
VII.e
VII.p
X.e
X.h
X.j
X.k
X.m
X.q
X.s
X.ad
XII.c
XIII.f
XIII.h
XIII.i
XV.m
XV.bn
XV.cq
XV.cr
XVI.k
XVI.av
XVI.bh
XVIII.c
Capecitabine
I.b
I.m
VII.a
VIII.af
X.k
XI.b
XII.d
XII.g
XII.af
XII.ai
Carbamazepine
I.a
I.b
I.c
I.d
I.e
I.k
I.l
II.a
II.b
IV.a
V.a
V.d
VII.a
VII.b
X.a
X.d
X.m
XII.a
XII.c
XII.d
XII.l
XII.s
XIII.b
XV.a
XV.b
XV.c
XV.e
XVI.ab
Chemotherapy, antineoplastic
I.a
I.b
I.c
I.d
I.f
I.g
I.h
I.k
I.l
I.m
I.n
I.v
I.w
I.x
I.y
I.aa
I.ad
I.ao
I.au
II.a
II.b
II.c
II.d
III.a
IV.a
IV.k
V.a
V.f
V.ab
VI.b
VI.c
VI.f
VII.a
VII.h
VIII.a
VIII.t
IX.f
IX.j
IX.o
X.c
X.d
X.f
X.g
X.k
X.n
XI.b
XI.k
XI.s
XII.a
XII.b
XII.c
XII.e
XII.f
XII.g
XII.l
XII.s
XII.ai
XII.bl
XIII.a
XIII.b
XIII.d
XV.c
XV.d
XV.f
XV.i
XV.l
XV.ak
XV.am
XV.ba
XVI.ab
XVI.af
XVI.bf
XVI.bl
XVI.bw
XVII.b
XVII.c
XVII.e
XVII.g
XVII.j
XVII.r
XVII.af
XIX.g
Cosmetic talc
I.m
VII.a
XV.e
XV.q
XV.da
XVI.w
E-cigarette - E-vaporizers - ENDS - Vaping - Dabbing
I.a
I.b
I.c
I.d
I.e
I.f
I.j
I.m
I.n
I.u
I.v
I.aw
I.ax
II.b
II.t
III.a
III.c
III.m
IV.a
IV.d
IV.f
IV.k
IV.n
IV.p
IV.q
IV.t
IV.v
IV.ad
IV.al
V.a
V.f
VII.a
VII.e
VII.h
VIII.d
VIII.al
VIII.an
VIII.ap
VIII.at
VIII.aw
VIII.bb
VIII.bc
IX.h
IX.af
X.b
X.k
X.q
X.aq
XI.b
XI.n
XI.y
XI.as
XI.aw
XI.ax
XI.ay
XII.a
XII.l
XII.ag
XIV.a
XV.c
XV.d
XV.e
XV.f
XV.g
XV.p
XV.x
XV.y
XV.ab
XV.ba
XV.bi
XVI.a
XVI.b
XVI.d
XVI.g
XVI.k
XVI.v
XVI.af
XVI.ai
XVI.bl
XVII.a
XVII.c
XVII.h
XVII.ac
XVIII.x
XIX.a
XIX.b
XIX.c
XIX.d
XIX.f
XIX.i
XIX.n
Etanercept
I.b
I.d
I.g
I.m
I.q
I.w
I.y
III.a
IV.a
V.d
V.f
V.m
VI.a
VI.d
VII.a
VIII.a
IX.q
X.b
X.d
X.e
X.f
X.j
X.k
X.m
X.s
X.ac
X.ar
XI.z
XII.d
XV.a
XV.c
XV.e
XV.ba
XVII.a
XVII.b
XVII.f
XVII.g
XVII.h
XVII.ab
Fenbufen
I.c
VII.a
Gabapentin
I.c
V.b
VII.a
VIII.a
VIII.q
IX.d
IX.p
XI.n
Highly active antiretroviral therapy - HAART
I.a
I.m
II.b
VII.a
X.a
X.i
X.k
XI.d
XV.c
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.u
I.v
I.w
I.y
I.aa
I.ad
I.aj
I.ax
II.b
II.d
III.m
IV.a
IV.c
IV.n
IV.y
IV.ab
IV.al
V.a
V.i
V.s
VI.a
VI.b
VII.a
VIII.t
IX.a
IX.d
IX.r
IX.ab
IX.ac
X.a
X.c
X.d
X.e
X.f
X.g
X.h
X.j
X.k
X.m
X.n
X.s
X.u
X.am
X.an
X.aw
X.ay
X.bi
XI.k
XI.u
XI.ac
XI.aq
XI.ar
XI.au
XII.a
XII.c
XII.d
XII.e
XII.g
XII.l
XII.n
XII.r
XII.s
XII.ai
XII.ax
XII.ba
XV.a
XV.b
XV.c
XV.d
XV.e
XV.f
XV.l
XV.v
XV.x
XV.ba
XV.ca
XV.co
XV.cp
XV.cw
XVI.k
XVI.v
XVI.w
XVI.bh
XVI.bm
XVI.bt
XVII.b
XVII.c
XVII.e
XVII.g
XVII.q
XVII.r
XIX.a
XIX.b
XIX.c
Indomethacin
I.c
IV.a
IV.f
VII.a
VIII.a
VIII.v
IX.e
Interferon alpha/beta
I.a
I.b
I.d
I.g
I.m
I.v
I.y
II.a
II.b
IV.a
IV.d
IV.w
V.a
VI.b
VI.d
VI.f
VII.a
VII.e
VIII.a
X.b
X.c
X.d
X.f
X.j
X.k
X.u
XI.k
XV.a
XV.c
XV.e
XV.f
XV.k
XVII.g
Iron pill (aspirated)
IV.m
IV.p
IV.s
VII.a
VIII.ar
XV.az
XV.bg
XV.bk
XIX.e
Loading more…